

Supplementary Table 2. Overview of the relevant information regarding genotyping, quality control, and imputation of the projects comprising the GenRisk dataset. The following columns are included: Project name: The name of the project. Samples: The number of samples used in the project. Genotype date: The date of genotyping. Array: The genotyping array used. SNPs included: The number of SNP included in the array. SNPs-QC: The number of SNP after quality control (QC). MCC-Spain samples: the number of samples belonging to MCC Spain. Control: The number of control samples. Case: The number of case samples. First author: The primary author of the reference article. Link to publication: A link to the publication related to the project.

| Project name: | Samples | | | | | | MCC-Spain samples | Genotype date: | Array: | SNPs markers included | SNPs-QC | Project name: | First author | Link to publication |
|---------------|---------|-----|------------|---------|---------|----------|-------------------|----------------|---|-----------------------|---------|-----------------------|-------------------------------------|---|
| | Breast | CLL | Colorectal | Control | Gastric | Prostate | | | | | | | | |
| CRCGen | 0 | 0 | 541 | 485 | 0 | 0 | 1026 | 2016 | Infinium Oncoarray-500 k | 533631 | 451568 | CRCGen | Mireia Obón-Santacana <i>et al.</i> | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574048/ |
| GASTRIC | 0 | 0 | 0 | 0 | 225 | 0 | 225 | 2016 | Illumina Infinium Omni2.5 Exome v1.3 | 2612357 | 2592364 | CNIO | Stephanie L Schmit <i>et al.</i> | https://academic.oup.com/jnci/article/111/2/146/5039592?login=false |
| PRACTICAL | 0 | 0 | 0 | 402 | 0 | 527 | 929 | 2018 | Infinium Oncoarray-500 k | 533631 | 485120 | PRACTICAL | Schumacher FR <i>et al.</i> | https://www.nature.com/articles/s41588-018-0142-8 |
| CNIO | 1179 | 390 | 890 | 1977 | 101 | 386 | 4923 | 2020/2021 | Illumina Global Screening Array-24 v3.0 | 660945 | 657992 | CNIO/CRCGen/PRACTICAL | National Cancer Institute | https://epi.grants.cancer.gov/gameon/ |

7103

Supplementary Table 3. Evaluation and Selection of PRSs for Cancer and Associated Risk Traits. List of PRS calculated and type of cancer associated. PRS evaluation: Assessment of PRS predictive power for corresponding trait.

| # | Trait Name | Risk factor of | PRS evaluation | |
|----|---|----------------|----------------|----------|
| | | | Test | p.value |
| 1 | Colorectal cancer | CRC | t.test | 8.0E-160 |
| 2 | Breast cancer | BC | t.test | 1.8E-226 |
| 3 | Prostate cancer | PC | t.test | <0.0001 |
| 4 | Alcohol intake frequency | CRC/BC/PC | ANOVA | <0.0001 |
| 5 | Alcohol consumed | CRC/BC/PC | t.test | 1.1E-239 |
| 6 | Freq. of drinking alcohol | CRC/BC/PC | ANOVA | <0.0001 |
| 7 | Average weekly alcohol consumption (beer and cider) | CRC/BC/PC | ANOVA | <0.0001 |
| 8 | Smoking status | CRC/BC/PC | ANOVA | <0.0001 |
| 9 | Number of cigarettes previously smoked daily (current cigar/pipe smokers) | CRC/BC/PC | ANOVA | <0.0001 |
| 10 | Never Smoker | CRC/BC/PC | ANOVA | <0.0001 |
| 11 | Weight | CRC/BC/PC | Pearson | <0.0001 |
| 12 | BMI (body mass index) | CRC/BC/PC | Pearson | <0.0001 |
| 13 | Waist circumference | CRC/BC/PC | Pearson | <0.0001 |
| 14 | Hip circumference | CRC/BC/PC | Pearson | <0.0001 |
| 15 | Standing height | CRC/BC/PC | Pearson | <0.0001 |
| 16 | Body fat % | CRC/BC/PC | Pearson | <0.0001 |
| 17 | Waist-hip ratio | CRC/BC/PC | Pearson | <0.0001 |
| 18 | Number of days/week walked 10+ minutes | CRC/BC/PC | Pearson | 4.5E-13 |
| 19 | Duration of Walks | CRC/BC/PC | Pearson | <0.0001 |
| 20 | Fresh fruit intake | CRC/BC/PC | Pearson | <0.0001 |
| 21 | Cooked vegetable intake | CRC/BC/PC | Pearson | <0.0001 |
| 22 | Oily fish intake | CRC/BC/PC | Pearson | <0.0001 |
| 23 | Processed meat intake | CRC/BC/PC | Pearson | <0.0001 |
| 24 | Beef intake | CRC/BC/PC | Pearson | 2.9E-66 |
| 25 | Poultry intake | CRC/BC/PC | Pearson | <0.0001 |

| | | | | |
|----|--|-----------|---------|-----------|
| 26 | Milk type: Skimmed | CRC/BC/PC | Pearson | 6.1E-50 |
| 27 | Bread intake | CRC/BC/PC | Pearson | <0.0001 |
| 28 | Cereal intake | CRC/BC/PC | Pearson | <0.0001 |
| 29 | Coffee intake | CRC/BC/PC | Pearson | 1.4E-08 |
| 30 | Coffee consumed | CRC/BC/PC | t.test | 7.6E-23 |
| 31 | Glucosamine | CRC/BC/PC | ANOVA | <0.0001 |
| 32 | Taking other prescription medications | CRC/BC/PC | t.test | <0.0001 |
| 33 | Nº of medications taken (Number of treatments/medications taken) | CRC/BC/PC | Pearson | <0.0001 |
| 34 | Paracetamol (Treatment/medication code) | CRC/BC/PC | t.test | 2.55E-257 |
| 35 | Ibuprofen (e.g. Nurofen) | CRC/BC/PC | t.test | 2.75E-73 |
| 36 | Aspirin | CRC/BC/PC | t.test | <0.0001 |
| 37 | Diabetes (Diabetes diagnosis) | CRC/BC/PC | t.test | <0.0001 |
| 38 | Age diabetes diagnosed | CRC/BC/PC | Pearson | 1.2E-57 |
| 39 | Essential hypertension | CRC/BC/PC | Pearson | 3.9E-49 |
| 40 | Cholesterol (biomarker) | CRC/BC/PC | Pearson | <0.0001 |
| 41 | HDL cholesterol (biomarker) | CRC/BC/PC | Pearson | <0.0001 |
| 42 | LDL cholesterol (biomarker) | CRC/BC/PC | Pearson | <0.0001 |
| 43 | Crohns disease (self-reported) | CRC | t.test | 2.5E-34 |
| 44 | Ulcerative colitis (self-reported) | CRC | t.test | 1.9E-51 |
| 45 | Diverticular disease/diverticulitis (self-reported) | CRC | t.test | 7.0E-28 |
| 46 | Malabsorption/coeliac disease (self-reported) | CRC | t.test | 3.4E-80 |
| 47 | Pulse rate (AR) | CRC/BC/PC | Pearson | <0.0001 |
| 48 | Uterine fibroids | BC | t.test | 1.8E-22 |
| 49 | Age when periods started (menarche) | BC | Pearson | <0.0001 |
| 50 | Age at menopause (last menstrual period) | BC | Pearson | <0.0001 |
| 51 | Length of menstrual cycle | BC | Pearson | 2.0E-16 |
| 52 | Number of live births | BC | Pearson | <0.0001 |
| 53 | Hyperplasia of prostate | PC | t.test | 1.5E-17 |
| 54 | Enlarged prostate | PC | t.test | 1.0E-38 |
| 55 | Vitamin D (nmol/L) | CRC/BC/PC | Pearson | <0.0001 |
| 56 | Glucose(mmol/L) | CRC/BC/PC | Pearson | <0.0001 |
| 57 | Red blood cell count (10 ¹² cells/Litre.) | CRC/BC/PC | Pearson | <0.0001 |
| 58 | Platelet count (10 ⁹ cells/Litre) | CRC/BC/PC | Pearson | <0.0001 |

| | | | | |
|----|---|-----------|---------|---------|
| 59 | Lymphocyte count | CRC/BC/PC | Pearson | <0.0001 |
| 60 | Monocyte count | CRC/BC/PC | Pearson | <0.0001 |
| 61 | globulina de transport de les hormones sexuals (variable "SHBG"). | BC | Pearson | <0.0001 |
| 62 | Testosterone (Only in females) | BC | Pearson | <0.0001 |
| 63 | Testosterone (male only) | PC | Pearson | <0.0001 |

Supplementary Table 4. Presents predictive performance metrics for CRC, BC, and PC prediction models, including final models and 10-fold cross-validation results.

| PRS model | Cohort | AUC | 95% CI | p.value* |
|-----------|----------|------|-------------|----------|
| CRC | bn_model | 0.74 | 0.72 - 0.76 | |
| | cv_f10 | 0.73 | 0.72 - 0.74 | 0.27 |
| BC | bn_model | 0.65 | 0.63 - 0.67 | |
| | cv_f10 | 0.65 | 0.64 - 0.66 | 0.95 |
| PC | bn_model | 0.77 | 0.76 - 0.79 | |
| | cv_f10 | 0.77 | 0.76 - 0.77 | 0.52 |

* p.value bn_model vs cross validations

Supplementary Table 5. Sex and age characteristics of the GenRisk study participants. CRC: Colorectal cancer; BC: Breast cancer; PC: Prostate cancer

| | | CRC | | BC | | PC | |
|--------------------|----------|-------------|----------|-------------|----------|-------------|----------|
| | | Control (%) | Case (%) | Control (%) | Case (%) | Control (%) | Case (%) |
| Total | | 1977 | 890 | 1334 | 1179 | 862 | 386 |
| | | 68.96 | 31.04 | 53.1 | 46.9 | 69.1 | 30.9 |
| Sex | Female | 56.5 | 36.9 | 100 | 100 | | |
| | Male | 43.5 | 63.1 | | | 100 | 100 |
| Age (years) | ≤45 | 12.3 | 3.4 | 18.5 | 20.3 | 4.1 | 0.3 |
| | (45, 55] | 18.6 | 13.8 | 23.9 | 30.3 | 11.5 | 9.1 |
| | (55,65] | 26.2 | 28.5 | 21.7 | 26.6 | 31.0 | 42.7 |
| | >65 | 42.9 | 54.3 | 35.9 | 22.8 | 53.5 | 47.9 |
| | Median | 64 | 67 | 59 | 55 | 66 | 65 |